Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Neuroendocrine Tumors × Capecitabine × Clear all

Phase

Status

Sponsor Class

OTHER 9 OTHER_GOV 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Rectal Neoplasms 7 Stomach Neoplasms 5 Nasopharyngeal Carcinoma 4 Colorectal Neoplasms 4 Breast Neoplasms 4 Esophageal Neoplasms 3 Neoplasm Metastasis 2 Colonic Neoplasms 2 Adenocarcinoma 2 Triple Negative Breast Neoplasms 1 Pancreatic Neoplasms 1 Oesophagogastric Cancer 1 Neuroendocrine Tumors 1 Nasopharyngeal Neoplasms 1 Mid-low Rectal Cancer 1 Metastatic Breast Cancer in the Brain 1 Locally Advanced Rectal Cancer With Liver Metastases 1 Locally Advanced Rectal Cancer 1 Liver Metastases of Colorectal Cancer 1 Immunotherapy 1 HER2 Positive Metastatic Breast Cancer 1 Colorectal Cancer Liver Metastasis 1 Cholangiocarcinoma 1 Breast Cancer Metastatic 1 Advanced Breast Cancer 1

Interventions

olaparib 1 copper dotatate CU-64 1 Tomography, Emission-Computed, Single-Photon 1 Positron Emission Tomography Computed Tomography 1 PM 01183 1 Lutetium-177 1 Iodine-124 1 Iodine-123 1 Injections 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07185672 2025-09-22

PReCedeNT

Tata Memorial Hospital

Phase 3 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡